Clark Estates Inc. NY Takes $2.24 Million Position in Haemonetics Corporation $HAE

Clark Estates Inc. NY bought a new stake in shares of Haemonetics Corporation (NYSE:HAE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 46,000 shares of the medical instruments supplier’s stock, valued at approximately $2,242,000. Clark Estates Inc. NY owned 0.10% of Haemonetics as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of HAE. EverSource Wealth Advisors LLC increased its stake in Haemonetics by 2,640.0% in the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares in the last quarter. Versant Capital Management Inc increased its position in Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 567 shares in the last quarter. Byrne Asset Management LLC acquired a new position in Haemonetics during the 3rd quarter worth approximately $42,000. Hantz Financial Services Inc. raised its stake in Haemonetics by 792.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 998 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new position in Haemonetics in the second quarter worth approximately $64,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

HAE has been the subject of several recent research reports. Raymond James Financial restated an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a report on Friday, November 14th. Barrington Research set a $94.00 price objective on shares of Haemonetics in a report on Friday, February 6th. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. BTIG Research reissued a “buy” rating and set a $88.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Finally, Mizuho lowered their target price on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics Stock Up 0.9%

HAE opened at $61.24 on Monday. Haemonetics Corporation has a fifty-two week low of $47.31 and a fifty-two week high of $87.32. The firm has a market capitalization of $2.85 billion, a P/E ratio of 16.87, a PEG ratio of 1.28 and a beta of 0.28. The company’s 50-day moving average is $71.94 and its 200 day moving average is $63.89. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 EPS for the quarter, beating the consensus estimate of $1.27 by $0.04. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. The firm had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter last year, the business posted $1.19 EPS. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Research analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.